EcoDrugPlus

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSPNYG00000017007
Gene Symbol: ACHE
3 Cross references
231 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSPNYG00000006277
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin Receptor Type-2b-Like

Ensembl ID : ENSPNYG00000000449
Gene Symbol: LOC102201968
3 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSPNYG00000005223
Gene Symbol: ADORA1
3 Cross references
204 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSPNYG00000007971
Gene Symbol: ADORA2A
3 Cross references
189 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSPNYG00000013352
Gene Symbol: ADORA2A
3 Cross references
198 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSPNYG00000017793
Gene Symbol: ADORA2B
3 Cross references
199 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSPNYG00000005712
Gene Symbol: ADORA3
3 Cross references
135 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSPNYG00000022120
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSPNYG00000022543
Gene Symbol: LOC102200284
3 Cross references
173 Possible Orthologues:

Adhesion Regulating Molecule 1

Ensembl ID : ENSPNYG00000023888
Gene Symbol: ADRM1
3 Cross references
194 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSPNYG00000000293
Gene Symbol: ADRA1B
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).